Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$17.21 - $25.28 $516,300 - $758,400
30,000 New
30,000 $701,000
Q1 2024

May 15, 2024

SELL
$13.02 - $21.3 $716,100 - $1.17 Million
-55,000 Reduced 78.57%
15,000 $228,000
Q4 2023

Feb 14, 2024

SELL
$6.68 - $18.81 $380,760 - $1.07 Million
-57,000 Reduced 44.88%
70,000 $1.2 Million
Q3 2023

Nov 14, 2023

BUY
$8.36 - $26.5 $466,487 - $1.48 Million
55,800 Added 78.37%
127,000 $1.06 Million
Q2 2023

Aug 14, 2023

BUY
$15.48 - $35.0 $869,976 - $1.97 Million
56,200 Added 374.67%
71,200 $1.77 Million
Q1 2023

May 15, 2023

SELL
$10.23 - $19.34 $255,750 - $483,500
-25,000 Reduced 62.5%
15,000 $225,000
Q4 2022

Feb 14, 2023

SELL
$5.01 - $11.83 $229,458 - $541,814
-45,800 Reduced 53.38%
40,000 $473,000
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $182,800 - $336,000
40,000 Added 87.34%
85,800 $507,000
Q2 2022

Aug 15, 2022

BUY
$3.74 - $10.66 $168,300 - $479,700
45,000 Added 5625.0%
45,800 $195,000
Q1 2022

May 13, 2022

SELL
$7.81 - $20.45 $4.99 Million - $13.1 Million
-639,100 Reduced 99.87%
800 $8,000
Q4 2021

Feb 11, 2022

BUY
$15.2 - $35.51 $8.85 Million - $20.7 Million
582,400 Added 1012.87%
639,900 $12.2 Million
Q3 2021

Nov 12, 2021

BUY
$21.78 - $40.45 $707,850 - $1.31 Million
32,500 Added 130.0%
57,500 $1.91 Million
Q2 2021

Aug 16, 2021

BUY
$32.5 - $48.96 $812,500 - $1.22 Million
25,000 New
25,000 $969,000
Q4 2018

Jan 30, 2019

SELL
$3.44 - $5.76 $664,952 - $1.11 Million
-193,300 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$5.15 - $14.0 $995,495 - $2.71 Million
193,300 New
193,300 $1.08 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.07B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.